- Home
- JHI vs CUE Comparison
JHI vs CUE Comparison
Compare JHI & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JHI | CUE |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.0M | 124.5M |
| IPO Year | 1994 | 2017 |
Fundamental Metrics
Financial Performance| Metric | JHI | CUE |
|---|---|---|
| Price | $13.23 | $24.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $120.00 |
| AVG Volume (30 Days) | 12.1K | ★ 70.8K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,466,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $12.50 | $0.17 |
| 52 Week High | $14.51 | $41.42 |
Technical Indicators
Market Signals| Indicator | JHI | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 52.53 | 49.46 |
| Support Level | $13.24 | $23.16 |
| Resistance Level | $13.56 | $32.60 |
| Average True Range (ATR) | 0.12 | 3.73 |
| MACD | 0.00 | -0.59 |
| Stochastic Oscillator | 73.59 | 18.74 |
Price Performance
Historical ComparisonAbout JHI John Hancock Investors Trust
John Hancock Investors Trust is a United States-based diversified, closed-end management investment company. It seeks to generate income for distribution to its shareholders. The secondary objective of the company is capital appreciation. The portfolio composition of the fund comprises corporate bonds, U.S. government agencies, preferred securities, asset-backed securities, common stocks, short-term investments, and others. The company's portfolio includes Corporate Bonds, Term Loans, U.S Government Agency, and Others.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.